FDA Opens Pilot to Cut the Wait on Phase 1 Trial Starts

The FDA on Sept. 15, 2026 opened a pilot program for an expedited investigational new drug (IND) application process, aiming to bring U.S. phase 1 trial start times in line with those in China and Australia.

The Food and Drug Administration opened a pilot program on Monday for an expedited investigational new drug application process, a change aimed squarely at one of the least glamorous and most expensive bottlenecks in American drug development: the wait between finishing preclinical work and dosing the first human volunteer.

The agency had signalled the initiative over the summer before formally opening it, according to Fierce Biotech. The stated benchmark is blunt and unusual for a U.S. regulator: the FDA wants domestic phase 1 trials to run on the same clock as those in China and Australia, two jurisdictions that have spent the past decade absorbing early-stage clinical work from American and European sponsors.

What an IND actually gates

An investigational new drug application is the filing a sponsor submits before it may give an experimental compound to humans. It packages the manufacturing chemistry, the animal toxicology and the proposed clinical protocol. Once filed, a statutory review window runs before the sponsor may proceed. In practice the elapsed time is longer than the window itself, because sponsors respond to information requests, resubmit sections, and sometimes absorb a clinical hold that stops the study before it starts.

That elapsed time is the quantity the pilot is designed to compress. For a small company, every month between a completed toxicology package and a first dose is burn with no data attached to it. Cash goes out, the clock on patent life and on investor patience keeps running, and nothing in the file changes. That is the arithmetic that has driven so many first-in-human studies offshore.

Why China and Australia became the comparison

Naming two foreign systems as the standard is a notable framing choice. Australia built its early-phase franchise on a human research ethics committee model that lets a site authorise a phase 1 study without a central agency filing, paired with a refundable research and development tax incentive that rebates a meaningful share of qualifying trial spend. The result is a country where a Western-standard phase 1 can begin quickly and cheaply, with data that regulators elsewhere will accept.

China's route is different. Reforms to its drug regulator over the past decade cut review queues, accepted more foreign preclinical packages, and paired the faster clearance with a very deep pool of trial-eligible patients. For oncology and cell therapy in particular, sponsors have gone there because both the paperwork and the recruitment move faster.

Neither pathway is free of trade-offs. Offshore phase 1 data still has to satisfy the FDA when a sponsor comes back for a U.S. pivotal trial, and questions of population representativeness and site oversight follow the file home. The pilot is, in effect, an argument that the agency would rather compete on speed than keep losing the work and inheriting the questions later.

Which sponsors have the most at stake

The companies with the most to gain are the ones for whom a phase 1 start is a financing event rather than a line on a Gantt chart. Clinical-stage biotechs running on a defined cash runway raise against catalysts, and "first patient dosed" is one of the few catalysts available before any efficacy data exists. Pulling that milestone forward changes the terms of a crossover round or a licensing conversation.

The companies with the most to gain are the ones for whom a phase 1 start is a financing event rather than a line on a Gantt chart.

Three groups sit closest to the benefit:

Venture-backed platform companies taking multiple assets into the clinic from one chemistry or biology engine, where the IND process is repeated several times a year and a saving compounds across the pipeline.
Academic spinouts with thin regulatory staffing, for whom an information request can consume months of a single consultant's attention.
Sponsors in modalities where offshoring is already the default — cell and gene therapy, radiopharmaceuticals, certain oncology bispecifics — and where the FDA's leverage over the eventual registration package depends on seeing the early work.

Large pharmaceutical companies benefit less directly. They have regulatory affairs departments built to absorb the current process, and their INDs rarely fail on resourcing. What faster starts do for them is change the calculus on where a first-in-human study is run, which matters for site contracts, contract research organisations and the clinical supply chain that follows the trial.

The details that will decide whether it works

A pilot is a narrow instrument by design. The questions that determine its significance are the ones sponsors will now be reading the program documents for: how many slots exist, what makes an application eligible, whether the expedited track applies to all modalities or only to those with well-trodden preclinical packages, and what happens to a sponsor who enters the pilot and then draws an information request.

There is also the resourcing question. Faster review without additional reviewer capacity is a reallocation, not a gain — time saved on pilot applications has to come from somewhere in the same queue. A credible readout on this program will eventually have to show that non-pilot INDs did not slow down while pilot ones sped up.

Market backdrop on the day

The announcement landed in a soft session for U.S. equities. As of the last trade at 18:51 GMT on Sept. 15, 2026, the S&P 500 tracker (NYSEARCA: SPY) was at $757.00, down 0.51% from the prior close of $760.88. The Nasdaq 100 proxy (NASDAQ: QQQ) sat at $704.42, off 0.67%, and the Dow tracker (NYSEARCA: DIA) was at $520.29, down 0.80%.

Regulatory process changes rarely move a share price on the day they are announced, and this one is unlikely to be an exception. Its effect shows up later and further down the capitalisation table — in how many first-in-human studies get announced from U.S. sites over the coming year, and in whether sponsors that had penciled in Sydney or Shanghai start reconsidering.

Key facts

Program opened: Sept. 15, 2026 — FDA pilot for an expedited investigational new drug (IND) application process
Stated goal: Bring U.S. phase 1 trial timelines on par with China and Australia
S&P 500 (SPY): $757.00, -0.51%, as of 18:51 GMT Sept. 15, 2026
Nasdaq 100 (QQQ): $704.42, -0.67%, as of 18:51 GMT Sept. 15, 2026

Frequently asked questions

What is an investigational new drug application?

An IND is the filing a drug sponsor submits to the FDA before it may administer an experimental compound to humans. It contains manufacturing and chemistry data, animal toxicology results and the proposed clinical protocol. A statutory review period runs after submission, and the sponsor may begin dosing only once that period passes without the agency placing the study on hold.

What did the FDA announce?

On Sept. 15, 2026, the FDA opened a pilot program offering an expedited investigational new drug application process. The agency had signalled the initiative during the summer before formally launching it. Its stated aim is to shorten the time between a completed preclinical package and the start of a phase 1 trial in the United States.

Why are China and Australia the comparison point?

Both jurisdictions have attracted substantial first-in-human trial work from Western sponsors. Australia allows site-level ethics committee authorisation of phase 1 studies and offers a research and development tax incentive, while China's regulator has cut review queues and offers deep patient recruitment pools. The FDA has set parity with those timelines as the pilot's benchmark.

Which companies benefit most from faster phase 1 starts?

Clinical-stage biotechs operating on a defined cash runway gain the most, because a first-patient-dosed milestone is often the catalyst they raise financing against. Platform companies filing several INDs a year and academic spinouts with thin regulatory staffing also stand to benefit. Large pharmaceutical firms already have departments built to absorb the existing process.

Does the pilot change the rules for phase 2 or phase 3 trials?

No. The program addresses the investigational new drug application, which is the gate to first-in-human phase 1 studies. Later-stage trials proceed under separate protocol amendments and review interactions. A faster phase 1 start can pull an entire development timeline forward, but the pilot itself targets only the initial clearance step.

How did markets react on the day of the announcement?

Broad U.S. indices were lower. As of the last trade at 18:51 GMT on Sept. 15, 2026, the S&P 500 tracker SPY was at $757.00, down 0.51%; the Nasdaq 100 proxy QQQ was at $704.42, down 0.67%; and the Dow tracker DIA stood at $520.29, down 0.80%. Regulatory process changes rarely move share prices immediately.

Sources

FDA launches pilot program to speed up sluggish phase 1 trials — Fierce Biotech

Photo: https://kaboompics.com/ · Pexels Licence — source